Navigation Links
NIST issues human milk and blood serum SRMs for contaminant measurements
Date:7/1/2009

vels five to 10 times higher than the median concentrations found in the U.S. population.

NIST SRMs have been rigorously tested and certified as having specific properties that researchers can trust as accurate within stated levels of uncertainty. The values stated on the certificates for these SRMs were measured by NIST and the CDC using a number of different methods including gas and liquid chromatography with mass spectrometry detection.


'/>"/>

Contact: Mark Esser
mark.esser@nist.gov
301-975-8735
National Institute of Standards and Technology (NIST)
Source:Eurekalert  

0

GOOD

Page: 1 2

Related biology news :

1. Chloroplast f and m Thioredoxins Discovered in Nonphotosynthetic Tissues
2. 200 journals join in theme issues on poverty and human development
3. Knocking out cell receptor may help block fat deposits in tissues, prevent weight gain
4. Media highlights in the November issues of Biophysical Journal
5. Media highlights in the January issues of Biophysical Journal
6. NAS to hold 2-day summit on energy issues
7. NHLBI issues first US von Willebrand Disease clinical practice guidelines
8. At ACS national meeting, global initiative set to tackle water issues
9. Expanded histology methods book covers processing of animal, plant, and microbial tissues
10. Experts tackle shipment issues for beneficial radiation sources
11. Origin of cells for connective tissues of skull and face challenged

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIST issues human milk and blood serum SRMs for contaminant measurements
NIST issues human milk and blood serum SRMs for contaminant measurements
(Date:11/4/2009)... N.Y., Oct. 21 What,s the cost of ... accidental death resulting from prescription medi...ood intentions, however, may be unaware that the l...ir teens from the ticking timebomb of prescription...n premium-quality medical supplies, has formed an ...
(Date:11/4/2009)...N.J., Oct. 26 BIO-key In...ader in finger-based biometric identification soft...tions at the AABB TXPO conference being held at th... 2009. BIO-key will provide hands-on product demon...echnology in booth #424. Also, at 5 PM on Monday, ...
(Date:11/4/2009)...PEL HILL Scientists at the University of North Ca...niversity of California, San Francisco have develo...ct new target diseases for existing drugs. , The... compares how similar the structures of all known ...ers -- known as ligands -- of disease targets with...
Breaking Biology News(10 mins):MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3BIO-key(R) International Exhibiting at AABB TXPO 2Study points to new uses, unexpected side effects of already existing drugs 2EFT BioTech Holdings Inc s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 12850 1EFT BioTech Holdings Inc s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 12850 2EFT BioTech Holdings Inc s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 12850 3Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 1Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 2Cosmetic surgery appeals to men women with appearance based rejection sensitivity 50413 1Cosmetic surgery appeals to men women with appearance based rejection sensitivity 50413 2
...ancer survivors might one day avoid the prospect o...nstead for an approach that would involve using st...rsity of Pittsburgh researchers who are studying t... new breast tissue. , In animal models, the resea...ved stem cells that are seeded onto microscopic sc...
...s of increased plant respiration in response to hi...d as they have not taken into account plants, abil... researchers from Oak Ridge National Laboratory. ,...ence, a team led by Tony King cites ORNL findings ...e stored in plants and soil with the acclimation o...
...g gene first identified in a cabbage-eating moth m...ative to viruses for gene therapy, researchers say...-characterized jumping genes, or transposons, to i...esired change, such as making the cell resistant t...e piggyBac transposon was five to 10 times better ...
Other Biology News:Fat stem cells being studied as option for breast reconstruction 2Plants' role in global warming re-examined 2Jumping gene could provide non-viral alternative for gene therapy 2Jumping gene could provide non-viral alternative for gene therapy 3
(Date:11/6/2009)...November 6 EUCODIS Bioscience, a c... marketing enzymes for the,chemical industry annou...eement with Bio Sidus, the leading biopharmaceutic...ent gives EUCODIS Bioscience exclusive access - fo..., proprietary collection of,psychrophilic bacteria...
(Date:11/6/2009)...wswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:O...oday announced updated results from a Phase II stu...comas metastatic to the lung in a poster presentat...Society Meeting held in Miami Beach, Florida, from...itled "A Phase II Study of Intravenous REOLYSIN (W...
(Date:11/5/2009)... hybrid . . . , Fuel economy ratings for the n...he www.fueleconomy.gov web site, which Oak Ridge...he U.S. Department of Energy and the U.S. Environm...es on the best fuel economy list are hybrid electr...way). "This list proves that hybrids have gone mai...
(Date:11/5/2009).... 5 DSM Pharmaceutical Products to...iance with Galenix, Saint Jean D,Illac, France, wh...ufacturing partner for Galenix commercial products...laborate on business development opportunities co-...d on the strength of Galenix in drug product devel...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...Conn. The State of Connecticut,s highest honor fo...gy, was presented this year to Yale Professor Tso...nductors. , The Connecticut Medal of Technology...ducation and the Connecticut Academy of Science a...th the Connecticut Medal of Science and is designe...
...10 Cardium Therapeutics,(Amex: CXM ) today repor...,quarter ended September 30, 2008, and outlined re...units: (1) InnerCool Therapies, (2) Tissue Repair,...http://www.newscom.com/cgi-bin/prnh/20051018/CARDI...es, Inc. The Company recently announced 510(k) cl...
... constant currency revenue growth of 12.9 percent,...rcent, constant currency), and improving profita... - Management reaffirms annual financial guidance... Hill-Rom Holdings,Inc. (NYSE: HRC ), announced u...uarter ended September 30, 2008 -- the second quar...
Other Biology Technology:Yale professor T.P. Ma awarded the Connecticut Medal of Technology 2Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 2Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 3Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 4Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 5Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 6Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 7Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 8Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 9Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 10Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19
GELase 50X Reaction Buffer from EPICENTRE Biotechnologies
Rat Anti-Mouse Macrophages, Metallophilic Monoclonal Antibody, Unconjugated from AbD Serotec
BMP-2 ELISA Kit from R&D Systems
Argarase from BioVision
Biology Products: